Cardiac amyloidosis natural history, complications and prognosis: Difference between revisions
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The presence or absence of cardiac involvement with amyloid is the most important prognostic factor.<ref name="pmid10319082">{{cite journal |author=Gertz MA, Lacy MQ, Dispenzieri A |title=Amyloidosis: recognition, confirmation, prognosis, and therapy |journal=[[Mayo Clinic Proceedings. Mayo Clinic]] |volume=74 |issue=5 |pages=490–4 |year=1999 |month=May |pmid=10319082 |doi=10.4065/74.5.490 |url=http://linkinghub.elsevier.com/retrieve/pii/S0025-6196(11)65130-6 |accessdate=2012-02-13}}</ref> | The presence or absence of cardiac involvement with amyloid is the most important prognostic factor.<ref name="pmid10319082">{{cite journal |author=Gertz MA, Lacy MQ, Dispenzieri A |title=Amyloidosis: recognition, confirmation, prognosis, and therapy |journal=[[Mayo Clinic Proceedings. Mayo Clinic]] |volume=74 |issue=5 |pages=490–4 |year=1999 |month=May |pmid=10319082 |doi=10.4065/74.5.490 |url=http://linkinghub.elsevier.com/retrieve/pii/S0025-6196(11)65130-6 |accessdate=2012-02-13}}</ref> | ||
==Complications== | ==Complications== | ||
| Line 22: | Line 19: | ||
* [[Cardiac tamponade]]<ref name="pmid1428240">{{cite journal |author=Navarro JF, Rivera M, Ortuño J |title=Cardiac tamponade as presentation of systemic amyloidosis |journal=[[International Journal of Cardiology]] |volume=36 |issue=1 |pages=107–8 |year=1992 |month=July |pmid=1428240 |doi= |url=}}</ref> | * [[Cardiac tamponade]]<ref name="pmid1428240">{{cite journal |author=Navarro JF, Rivera M, Ortuño J |title=Cardiac tamponade as presentation of systemic amyloidosis |journal=[[International Journal of Cardiology]] |volume=36 |issue=1 |pages=107–8 |year=1992 |month=July |pmid=1428240 |doi= |url=}}</ref> | ||
* [[Stroke]] and [[claudication]] due to [[intracardiac thrombus]] causing [[thromboembolism]]. | * [[Stroke]] and [[claudication]] due to [[intracardiac thrombus]] causing [[thromboembolism]]. | ||
==Prognosis== | |||
Cardiac amyloidosis is a chronic and progressive condition. A cardiologist may estimate the prognosis according to the thickness of the [[left ventricle]] and to the degree of restriction in the heart (diastolic dysfunction). | |||
==References== | ==References== | ||
Revision as of 00:15, 5 May 2013
|
Cardiac amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiac amyloidosis natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Cardiac amyloidosis natural history, complications and prognosis |
|
FDA on Cardiac amyloidosis natural history, complications and prognosis |
|
CDC onCardiac amyloidosis natural history, complications and prognosis |
|
Cardiac amyloidosis natural history, complications and prognosis in the news |
|
Blogs on Cardiac amyloidosis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor: Cafer Zorkun, M.D., Ph.D. [2]; Lakshmi Gopalakrishnan, M.B.B.S. [3]
Overview
The presence or absence of cardiac involvement with amyloid is the most important prognostic factor.[1]
Complications
- Congestive heart failure
- Sudden cardiac death
- Myocardial infarction
- Atrial fibrillation
- Tachyarrhythmias
- Ventricular arrhythmias
- Sick sinus syndrome (occasionally)
- Heart blocks and other conduction defects
- Syncope or presyncope
- Increased sensitivity to digoxin with the potential for digoxin toxicity and related arrhythmias. The amyloid protein tends to bind the digoxin and increase its local concentration in the conduction system for instance.
- Ascites (fluid accumulation in the abdomen)
- Cardiac tamponade[2]
- Stroke and claudication due to intracardiac thrombus causing thromboembolism.
Prognosis
Cardiac amyloidosis is a chronic and progressive condition. A cardiologist may estimate the prognosis according to the thickness of the left ventricle and to the degree of restriction in the heart (diastolic dysfunction).
References
- ↑ Gertz MA, Lacy MQ, Dispenzieri A (1999). "Amyloidosis: recognition, confirmation, prognosis, and therapy". Mayo Clinic Proceedings. Mayo Clinic. 74 (5): 490–4. doi:10.4065/74.5.490. PMID 10319082. Retrieved 2012-02-13. Unknown parameter
|month=ignored (help) - ↑ Navarro JF, Rivera M, Ortuño J (1992). "Cardiac tamponade as presentation of systemic amyloidosis". International Journal of Cardiology. 36 (1): 107–8. PMID 1428240. Unknown parameter
|month=ignored (help)